Royal Bank of Canada
TBPH icon

Royal Bank of Canada’s Theravance Biopharma TBPH Stock Holding History

Royal Bank of Canada’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Buy
8,907
+5,097
+134% +$84.4K ﹤0.01% 5154
2026
Q1 		$62K Sell
3,810
-5,654
-60% -$100K ﹤0.01% 5378
2025
Q4 		$177K Buy
9,464
+1,024
+12% +$17K ﹤0.01% 4844
2025
Q3 		$123K Sell
8,440
-495,176
-98% -$6.26M ﹤0.01% 5395
2025
Q2 		$5.55M Buy
503,616
+501,127
+20,134% +$4.87M ﹤0.01% 2492
2025
Q1 		$22K Sell
2,489
-2,593
-51% -$24.1K ﹤0.01% 5891
2024
Q4 		$48K Buy
5,082
+1,334
+36% +$12.1K ﹤0.01% 5724
2024
Q3 		$30K Sell
3,748
-794
-17% -$6.88K ﹤0.01% 5942
2024
Q2 		$38K Buy
4,542
+1,671
+58% +$15.1K ﹤0.01% 5781
2024
Q1 		$26K Sell
2,871
-14,144
-83% -$131K ﹤0.01% 5809
2023
Q4 		$192K Buy
17,015
+7,448
+78% +$75K ﹤0.01% 5138
2023
Q3 		$83K Buy
9,567
+3,035
+46% +$29.3K ﹤0.01% 5511
2023
Q2 		$68K Buy
6,532
+1,649
+34% +$18.2K ﹤0.01% 5613
2023
Q1 		$53K Sell
4,883
-6,070
-55% -$64.2K ﹤0.01% 5594
2022
Q4 		$123K Buy
10,953
+4,343
+66% +$45.6K ﹤0.01% 5297
2022
Q3 		$67K Buy
6,610
+6,148
+1,331% +$57.6K ﹤0.01% 5575
2022
Q2 		$4K Sell
462
-12,570
-96% -$116K ﹤0.01% 6758
2022
Q1 		$124K Sell
13,032
-11,804
-48% -$116K ﹤0.01% 5489
2021
Q4 		$275K Buy
24,836
+3,723
+18% +$32.4K ﹤0.01% 5025
2021
Q3 		$157K Sell
21,113
-3,943
-16% -$44.1K ﹤0.01% 5380
2021
Q2 		$364K Buy
25,056
+3,711
+17% +$69.7K ﹤0.01% 4548
2021
Q1 		$436K Sell
21,345
-791
-4% -$15K ﹤0.01% 4304
2020
Q4 		$393K Sell
22,136
-622
-3% -$11.2K ﹤0.01% 4339
2020
Q3 		$337K Sell
22,758
-1,728
-7% -$32.4K ﹤0.01% 4169
2020
Q2 		$513K Sell
24,486
-595
-2% -$15.3K ﹤0.01% 3749
2020
Q1 		$580K Buy
25,081
+1,365
+6% +$34.2K ﹤0.01% 3479
2019
Q4 		$614K Buy
23,716
+4,114
+21% +$79.9K ﹤0.01% 3828
2019
Q3 		$382K Buy
19,602
+910
+5% +$18.4K ﹤0.01% 4018
2019
Q2 		$305K Buy
18,692
+318
+2% +$6.44K ﹤0.01% 4197
2019
Q1 		$417K Buy
18,374
+396
+2% +$10K ﹤0.01% 3863
2018
Q4 		$460K Sell
17,978
-654
-4% -$17.7K ﹤0.01% 3773
2018
Q3 		$609K Buy
18,632
+882
+5% +$24K ﹤0.01% 3760
2018
Q2 		$403K Buy
17,750
+1,086
+7% +$25.8K ﹤0.01% 3945
2018
Q1 		$404K Buy
16,664
+3,042
+22% +$83.5K ﹤0.01% 3850
2017
Q4 		$380K Sell
13,622
-2,010
-13% -$59.5K ﹤0.01% 3979
2017
Q3 		$535K Buy
15,632
+5,843
+60% +$191K ﹤0.01% 3736
2017
Q2 		$390K Sell
9,789
-667
-6% -$25.6K ﹤0.01% 3862
2017
Q1 		$385K Sell
10,456
-1,723
-14% -$55K ﹤0.01% 3847
2016
Q4 		$388K Sell
12,179
-9,536
-44% -$296K ﹤0.01% 3969
2016
Q3 		$787K Buy
21,715
+11,505
+113% +$320K ﹤0.01% 3313
2016
Q2 		$232K Sell
10,210
-277
-3% -$5.98K ﹤0.01% 4309
2016
Q1 		$197K Hold
10,487
– – ﹤0.01% 4381
2015
Q4 		$172K Sell
10,487
-28
-0.3% -$444 ﹤0.01% 4624
2015
Q3 		$116K Hold
10,515
– – ﹤0.01% 4694
2015
Q2 		$137K Buy
10,515
+9,912
+1,644% +$154K ﹤0.01% 4642
2015
Q1 		$10K Sell
603
-623
-51% -$11.4K ﹤0.01% 5578
2014
Q4 		$18K Sell
1,226
-9,868
-89% -$172K ﹤0.01% 5439
2014
Q3 		$255K Buy
11,094
+10,243
+1,204% +$297K ﹤0.01% 4018
2014
Q2 		$27K Buy
+851
New +$25.6K ﹤0.01% 5099

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Royal Bank of Canada's TBPH Position: Q2 2026 in Review

Royal Bank of Canada increased its Theravance Biopharma (TBPH) stake by 134% in Q2 2026, buying an estimated $84.4K and bringing the position to 8,907 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #5154.

Royal Bank of Canada first reported a position in TBPH in Q2 2014 and has held it in 49 quarters since. The position peaked at $5.55M in Q2 2025. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Royal Bank of Canada held 8,907 shares of Theravance Biopharma worth $151K as of Q2 2026.
  • Royal Bank of Canada bought 5,097 Theravance Biopharma shares in Q2 2026, an estimated $84.4K.
  • Theravance Biopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #5154 holding.
  • Royal Bank of Canada first reported a position in Theravance Biopharma in Q2 2014 and has held it in 49 quarters since.
  • Royal Bank of Canada's Theravance Biopharma position peaked at $5.55M in Q2 2025.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.